Literature DB >> 210164

Hepatic alpha-adrenergic receptors. Identification and subcellular localization using [3H]dihydroergocryptine.

W R Clarke, L R Jones, R J Lefkowitz.   

Abstract

Recently, several workers have shown that adrenergic control of hepatic carbohydrate metabolism has the characteristics of an alpha-receptor-mediated process. Using the rat liver membrane preparation of Neville (Neville, D. (1968) Biochim. Biophys. Acta 154, 540-552), alpha-adrenergic receptors have been identified using the ligand [3H]dihydroergocryptine. The receptors are saturable and of high affinity. Scatchard analysis yields a KD of 1.8 nM with 1.7 +/- 0.55 pmol of sites/mg of protein. Competition of dihydroergocryptine binding with various pharmacologic agents yields the typical (alpha-adrenergic potency series: (-)-epinephrine greater than (-)-norepinephrine greater than (-)-isoproterenol. (-)-Isomers are more potent than (+)-isomers. The alpha-blocker phentolamine is 3.4 orders of magnitude more potent than the beta-blocker propranolol. To determine subcellular localization of alpha-adrenergic receptors, livers were fractionated into a crude homogenate, a 1500 X g pellet, and the purified membrane preparation used previously for binding. Specific dihydroergocryptine binding, ouabain-inhibitable (Na,K)-ATPase, and F--stimulated adenylate cyclase activities, were followed in these fractions. Specific binding was enriched, relative to that in the crude homogenate, 2.88-fold in the pellet and 6.28-fold in the membranes. Similarly, (Na,K)-ATPase acticity was enriched 2.6-fold in the pellet and 7.1-fold in the membranes while adenylate cyclase activity was enriched 2.9-fold in the pellet and 3.5-fold in the membranes. It is concluded that hepatic alpha-adrenergic receptors are likely concentrated in the plasma membranes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210164

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Rocastine (AHR-11325), a rapid acting, nonsedating antihistamine.

Authors:  J C Nolan; D J Stephens; A G Proakis; C A Leonard; D N Johnson; B F Kilpatrick; M H Foxwell; J M Yanni
Journal:  Agents Actions       Date:  1989-08

Review 2.  The hepatic adrenergic receptors.

Authors:  P H Schmelck; J Hanoune
Journal:  Mol Cell Biochem       Date:  1980-12-10       Impact factor: 3.396

3.  Proceedings of the British Pharmacological Society. University of Leicester, 6th-8th July, 1983. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

4.  Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor.

Authors:  M C Michel; R Büscher; J Kerker; H Kraneis; W Erdbrügger; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

5.  Further characterization of [3H] flunitrazepam binding sites on cultured mouse astroglia.

Authors:  M Tardy; C Fages; G Dupre; M F Costa; J Bardakdjian; B Rolland
Journal:  Neurochem Res       Date:  1985-06       Impact factor: 3.996

6.  Agonist versus antagonist binding to alpha-adrenergic receptors.

Authors:  B B Hoffman; T Michel; D M Kilpatrick; R J Lefkowitz; M E Tolbert; H Gilman; J N Fain
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

7.  [Prostaglandin interaction in the human liver].

Authors:  I Virgolini; K Weiss; M Hermann; C Müller; H Sinzinger
Journal:  Klin Wochenschr       Date:  1989-12-15

8.  Human hepatocellular cancers show decreased prostaglandin E1 binding capacity.

Authors:  I Virgolini; H Sinzinger; C Müller; M Hermann
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.